Yara Abdou, Assistant Professor at the University of North Carolina, shared a post on X:
“OlympiA: Updated analysis at median fu of 6.1 years (max 9.6 years)
Olaparib continues to demonstrate clinically meaningful increase in IDFS, DDFS and OS in patients with gBRCAm, high risk, HER2- BC across all subgroups.
No increased risk of MDS or AML.”
Yara Abdou, MD, is an Assistant Professor at the University of North Carolina at Chapel Hill specializing in early-stage and metastatic breast cancer. Her research centers on developing targeted immunotherapies to treat diverse breast cancer subtypes, with a focus on understanding racial differences in tumor biology and the immune microenvironment. Working with basic and translational scientists, she aims to improve treatment efficacy and address disparities in outcomes for minority women with breast cancer.
